» Articles » PMID: 23849283

Estimating a WTP-based Value of a QALY: the 'chained' Approach

Overview
Journal Soc Sci Med
Date 2013 Jul 16
PMID 23849283
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

A major issue in health economic evaluation is that of the value to place on a quality adjusted life year (QALY), commonly used as a measure of health care effectiveness across Europe. This critical policy issue is reflected in the growing interest across Europe in development of more sound methods to elicit such a value. EuroVaQ was a collaboration of researchers from 9 European countries, the main aim being to develop more robust methods to determine the monetary value of a QALY based on surveys of the general public. The 'chained' approach of deriving a societal willingness-to-pay (WTP) based monetary value of a QALY used the following basic procedure. First, utility values were elicited for health states using the standard gamble (SG) and time trade off (TTO) methods. Second, a monetary value to avoid some risk/duration of that health state was elicited and the implied WTP per QALY estimated. We developed within EuroVaQ an adaptation to the 'chained approach' that attempts to overcome problems documented previously (in particular the tendency to arrive at exceedingly high WTP per QALY values). The survey was administered via Internet panels in each participating country and almost 22,000 responses achieved. Estimates of the value of a QALY varied across question and were, if anything, on the low side with the (trimmed) 'all country' mean WTP per QALY ranging from $18,247 to $34,097. Untrimmed means were considerably higher and medians considerably lower in each case. We conclude that the adaptation to the chained approach described here is a potentially useful technique for estimating WTP per QALY. A number of methodological challenges do still exist, however, and there is scope for further refinement.

Citing Articles

A systematic review on the direct approach to elicit the demand-side cost-effectiveness threshold: Implications for low- and middle-income countries.

Nu Vu A, Van Hoang M, Lindholm L, Sahlen K, Nguyen C, Sun S PLoS One. 2024; 19(2):e0297450.

PMID: 38329955 PMC: 10852300. DOI: 10.1371/journal.pone.0297450.


Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method.

Peng Q, Yin Y, Liang M, Zhao M, Shao T, Tang Y Cost Eff Resour Alloc. 2023; 21(1):80.

PMID: 37915053 PMC: 10621116. DOI: 10.1186/s12962-023-00487-z.


Estimating the monetary value of a Quality-Adjusted Life-Year in Quebec.

Kouakou C, He J, Poder T Eur J Health Econ. 2023; 25(5):787-811.

PMID: 37656261 DOI: 10.1007/s10198-023-01625-3.


Protocol for estimating the willingness-to-pay-based value for a quality-adjusted life year to aid health technology assessment in India: a cross-sectional study.

Chugh Y, Jyani G, Trivedi M, Albert S, Kar S, Patro B BMJ Open. 2023; 13(2):e065591.

PMID: 36797026 PMC: 9936284. DOI: 10.1136/bmjopen-2022-065591.


Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic review.

Iino H, Hashiguchi M, Hori S PLoS One. 2022; 17(4):e0266934.

PMID: 35421181 PMC: 9009631. DOI: 10.1371/journal.pone.0266934.